Postural orthostatic tachycardia syndrome treatment guidelines

Jump to navigation Jump to search

Postural orthostatic tachycardia syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating POTS from Other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Other Diagnostic Studies

Treatment

ACC/AHA/ESC Treatment Guidelines

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Postural orthostatic tachycardia syndrome treatment guidelines On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Postural orthostatic tachycardia syndrome treatment guidelines

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Postural orthostatic tachycardia syndrome treatment guidelines

CDC on Postural orthostatic tachycardia syndrome treatment guidelines

Postural orthostatic tachycardia syndrome treatment guidelines in the news

Blogs on Postural orthostatic tachycardia syndrome treatment guidelines

Directions to Hospitals Treating Postural orthostatic tachycardia syndrome

Risk calculators and risk factors for Postural orthostatic tachycardia syndrome treatment guidelines

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

ACC/AHA/ESC Practice Guidelines. Recommendations for Treatment of Postural Orthostatic Tachycardia Syndrome[1] (DO NOT EDIT)

Class IIa

Medical

Nonpharmacologic

1) Increase salt and fluid intake (Level of Evidence: B)

2) Head-up tilt sleep (Level of Evidence: B)

3) Physical maneuvers (Level of Evidence: B)

4) Compression stockings (Level of Evidence: B)

Pharmacologic

1) Mineralocorticoids: Fludrocortisone (Level of Evidence: B)

2) Beta blockers: Bisoprolol (Level of Evidence: B)

3) Beta Blockers plus mineralocorticoids: Bisoprolol plus Fludrocortisone (Level of Evidence: B)

Class IIb

Pharmacologic

1) Central sympatholytic agents: Clonidine (Level of Evidence: B)

2) Peripherally acting: Midodrine (Level of Evidence: B)

3) Centrally acting: Methylphenidate (Level of Evidence: C)

4) Serotonin-specific reuptake inhibitor: Fluoxetine (Level of Evidence: C)

5) Others: Erythropoietin (Level of Evidence: B), Ergotamine/octroetide (Level of Evidence: B), Phenobarbitone (Level of Evidence: C)

Class III

Interventional

Catheter ablation/surgical

1) Sinus node modification, catheter ablation (Level of Evidence: B)


References

  1. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". Journal of the American College of Cardiology. 42 (8): 1493–531. PMID 14563598. Retrieved 2012-09-12. Unknown parameter |month= ignored (help)